Acknowledgements This work was supported by the Natural Science foundation of Jiangsu (grant number: BK20131439) and the Jiangsu Province Institute of Cancer Research Foundation (grant number: ZK201203) and the 2012 International Exchange Support Program of Jiangsu Health. References 1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013,63(1):11–30.PubMedCrossRef 2. Yang L, et al.: Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005,14(1):243–50.PubMed 3. Cannistra 4EGI-1 SA: Cancer
of the ovary. N Engl J Med 2004,351(24):2519–29.PubMedCrossRef 4. Benedetti Panici P, et al.: Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 2007,14(3):1136–42.PubMedCrossRef 5. Park JY, et al.: Secondary cytoreductive surgery in the management of platinum-sensitive
selleckchem recurrent epithelial ovarian cancer. J Surg Oncol 2010,101(5):418–24.PubMed 6. Landoni F, et al.: Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look find more laparotomy. Acta Obstet Gynecol Scand 1998,77(2):233–7.PubMedCrossRef 7. Boran N, et al.: Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer. J Surg Oncol 2012,106(4):369–75.PubMedCrossRef 8. Chi DS, et al.: Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006,106(9):1933–9.PubMedCrossRef 9. Bristow RE, Puri I, Chi DS: Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009,112(1):265–74.PubMedCrossRef 10. Harter P, et Sorafenib in vivo al.: Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006,13(12):1702–10.PubMedCrossRef 11. Harter P, et al.: Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of
the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 2009,16(5):1324–30.PubMedCrossRef 12. Wang F, et al.: CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J Ovarian Res 2013,6(1):14.PubMedCrossRef 13. Tian WJ, et al.: A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol 2012,19(2):597–604.PubMedCrossRef 14. Moertel CG, Hanley JA: The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976,38(1):388–94.PubMedCrossRef 15. Therasse P, et al.: New guidelines to evaluate the response to treatment in solid tumors.